Condition: Rescue Stenting · Sponsor: Acandis GmbH
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Goal of the study is to evaluate the efficacy and safety of acute permanent stenting of symptomatic intracranial stenosis following unsuccessful recanalization by thrombectomy in acute ischemic stroke with large vessel occlusion using the self-expandable CREDO® heal Stent.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients, treated with CREDO® heal according to IFU * Over 18 years old * With acute persistent vascular occlusion due to high grade intracranial artery stenosis in the anterior or posterior circulation for which alternative therapy concepts are not considered or fail * With suspected underlying stenosis of the occluded artery, which is suitable for PTA and stenting according to the treating physician's assessment and/or persistent occlusion after failed recanalization by mechanical thrombectomy of the target region * With small to moderate infarct core prior to initiation of thrombectomy (CT ASPECTS 6-10, DWI lesion \< 70 ml) * With symptoms onset less than 24 hours before start of the procedure * Treated with study device following at least one futile mechanical recanalization attempt with a stent retriever, direct aspiration or combination of both * With pre-stroke disability mRS 0-2 Exclusion Criteria: * Any contraindication according to IFU and patients: * With atherosclerotic (probable according to clinical, anamnestic or laboratory chemical testing) vessel constrictions (high-grade intracranial stenoses \> 70 %) with significant circulatory disturbance (haemodynamic infarct pattern and signs of restricted collaterals) and recurrent symptoms in spite of medical therapy * With contraindication against treatment with anti-platelet medication * Participating in another trial
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Institut für Radiologie und Neuroradiologie, Klinikum Aschaffenburg-Alzenau | Aschaffenburg, Germany | Recruiting |
| Klinik für Diagnostische Radiologie und Neuroradiologie; Universitätsklinikum Augsburg | Augsburg, Germany | Recruiting |
| Klinik für Diagnostische und Interventionelle Neuroradiologie; Universitätsklinikum Bonn | Bonn, Germany | Recruiting |
| Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin, Klinikum Bremerhaven-Reinkenheide | Bremerhaven, Germany | Recruiting |
| Institut und Poliklinik für Diagnostische und Interventionelle Neuroradiologie, Universitätsklinikum Dresden | Dresden, Germany | Recruiting |
| Klinik für Radiologie und Neuroradiologie, Sana Klinikum | Duisburg, Germany | Recruiting |
| Diagnostische und interventionelle Radiologie, Helios Klinikum Erfurt | Erfurt, Germany | Recruiting |
| Diagnostische und Interventionelle Neuroradiologie, Universitätsmedizin Halle | Halle, Germany | Recruiting |
| Abteilung für Radiologie, Neuroradiologie und Nuklearmedizin, Asklepios Klinikum Altona | Hamburg, Germany | Recruiting |
| Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Universitätsklinikum Hamburg-Eppendorf | Hamburg, Germany | Recruiting |
| Radiologie / Neuroradiologie, Askleopis Klinik St. Georg | Hamburg, Germany | Recruiting |
| Klinik für Neuroradiologie, Westpfalz-Klinikum | Kaiserslautern, Germany | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.